Aurora Cannabis vs Guobang Pharma: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Aurora Cannabis Inc (ACB)

Q3 20268 Aug – 5 Oct 2026

▲2

International medical cannabis keeps growing Aurora's international medical revenue rose 17% to C$43.3 million, with 64% of sales now outside Canada and a 58% gross margin. This high-margin growth is the core reason the business is worth more, even as total revenue fell on a Canadian reimbursement cut.
Shows the fundamental business driver behind Aurora's value, separate from the takeover noise.
Curaleaf's takeover bid lifts the shares Curaleaf launched a hostile bid worth $4 per Aurora share, a 45% premium, later saying it intends to raise it to $5. The offer gives shareholders a concrete cash-and-stock alternative and has pushed ACB sharply higher as investors weigh the deal.
The bid is the single biggest force moving ACB's price this period.
Aurora resists, arguing it is stronger alone Aurora urged shareholders to take no action, highlighting its $149 million cash and no debt versus Curaleaf's roughly $1 billion in debt. The fight keeps a floor under the stock but leaves the outcome uncertain until the bid expires December 4.
Explains the counterweight to the bid and why the situation is not a simple win for ACB holders.

September 20268 Aug – 5 Oct 2026

▲2

International medical cannabis keeps growing Aurora's international medical revenue rose 17% to C$43.3 million, with 64% of sales now outside Canada and a 58% gross margin. This high-margin growth is the core reason the business is worth more, even as total revenue fell on a Canadian reimbursement cut.
Shows the fundamental business driver behind Aurora's value, separate from the takeover noise.
Curaleaf's takeover bid lifts the shares Curaleaf launched a hostile bid worth $4 per Aurora share, a 45% premium, later saying it intends to raise it to $5. The offer gives shareholders a concrete cash-and-stock alternative and has pushed ACB sharply higher as investors weigh the deal.
The bid is the single biggest force moving ACB's price this period.
Aurora resists, arguing it is stronger alone Aurora urged shareholders to take no action, highlighting its $149 million cash and no debt versus Curaleaf's roughly $1 billion in debt. The fight keeps a floor under the stock but leaves the outcome uncertain until the bid expires December 4.
Explains the counterweight to the bid and why the situation is not a simple win for ACB holders.

Latest8 Aug – 5 Oct 2026

▲2

International medical cannabis keeps growing Aurora's international medical revenue rose 17% to C$43.3 million, with 64% of sales now outside Canada and a 58% gross margin. This high-margin growth is the core reason the business is worth more, even as total revenue fell on a Canadian reimbursement cut.
Shows the fundamental business driver behind Aurora's value, separate from the takeover noise.
Curaleaf's takeover bid lifts the shares Curaleaf launched a hostile bid worth $4 per Aurora share, a 45% premium, later saying it intends to raise it to $5. The offer gives shareholders a concrete cash-and-stock alternative and has pushed ACB sharply higher as investors weigh the deal.
The bid is the single biggest force moving ACB's price this period.
Aurora resists, arguing it is stronger alone Aurora urged shareholders to take no action, highlighting its $149 million cash and no debt versus Curaleaf's roughly $1 billion in debt. The fight keeps a floor under the stock but leaves the outcome uncertain until the bid expires December 4.
Explains the counterweight to the bid and why the situation is not a simple win for ACB holders.